0OIR Alk -- Financial Calendar For The 2023 Financial Year
20 December 2022 - 3:33AM
UK Regulatory
TIDMALK TIDMB
2023 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY /
AKBLF):
-- 6 January 2023: Silent period
-- 3 February 2023: Annual report 2022
-- 23 March 2023 at 4.00p.m.: Annual General Meeting to be held at
ALKBøge Allé 12970 Hørsholm, Denmark Written requests to
have specific business transacted at the AGM will be included in
the agenda if received by the company on 8 February 2023 at the
latest (may be e-mailed to investor@alk.net)
-- 11 April 2023: Silent period
-- 9 May 2023: Three-month interim report (Q1) 2023
-- 27 July 2023: Silent period
-- 24 August 2023: Six-month interim report (Q2) 2023
-- 18 October 2023: Silent period
-- 15 November 2023: Nine-month interim report (Q3) 2023
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile
+45 2261 2525
About ALK
ALK is a global specialty pharmaceutical company focused on
allergy and allergic asthma. It markets allergy immunotherapy
treatments and other products and services for people with allergy
and allergy doctors. Headquartered in Hørsholm, Denmark, ALK
employs around 2,600 people worldwide and is listed on Nasdaq
Copenhagen. Find more information at www.alk.net.
Attachment
-- InvestorNews_19Dec22_FinancialCalendar
https://ml-eu.globenewswire.com/Resource/Download/3c38759c-5bf8-46e7-ae42-380ba7d481e1
(END) Dow Jones Newswires
December 19, 2022 11:33 ET (16:33 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Apr 2023 to Apr 2024